Kymab, Roche agree to evaluate KY1044, anti-PD-L1 immunotherapy in solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kymab Group Ltd. announced a clinical trial agreement with F. Hoffmann-La Roche Ltd.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login